Exploring the Therapeutic Potential of Hepar Sulph. and Silicea in Fistula in Ano Management: A randomized controlled trial

DR. RAVIRAJ PRAKASHRAO PORE[1], DR. MIRZA SADATH BAIG[2], DR. RAJESH ISHWAR TUNGENWAR[3], DR. SHANKAR GOVIND YAMULWAD[4]

[1]*Associate Professor, Department of Pathology, Mauli Homoeopathic Medical College & Research Institute Tondar (Udgir)*

[2]*Professor, Department of Forensic Medicine & Toxicology, Mauli Homoeopathic Medical College & Research Institute Tondar (Udgir)*

[3]*Assistant Professor, Department of Human Anatomy Mauli Homoeopathic Medical College & Research Institute Tondar (Udgir)*

[4]*Assistant Professor, Department of Community Medicine Mauli Homoeopathic Medical College & Research Institute Tondar (Udgir)*

Abstract—

Background

Fistula in ano is a common and often debilitating condition that can cause pain, discharge, and recurrent infections. Conventional treatments typically involve surgical interventions, which may not always be desirable due to the risk of complications or the need for a prolonged recovery period. Homeopathy offers a potential alternative with remedies such as Hepar Sulph. and Silicea, which are thought to promote healing and reduce inflammation. However, their efficacy in fistula management has not been extensively studied. Objective

This study aims to evaluate the therapeutic potential of Hepar Sulph. and Silicea in managing fistula in ano, focusing on their ability to alleviate symptoms, promote healing, and reduce recurrence of infections.

Methods:

A clinical trial was conducted involving 60 patients diagnosed with fistula in ano, randomly assigned to receive either Hepar Sulph. or Silicea treatment. The remedies were prescribed based on individual symptom profiles and potency (30C). Patients were monitored for changes in pain, discharge, healing of the fistula, and recurrence rates over a 6-month period. Clinical evaluations, including imaging and symptom tracking, were performed at baseline, 3 months, and 6 months.

Results

Both groups demonstrated significant improvements in symptom reduction. Patients treated with Hepar Sulph. showed faster reduction in pain and discharge, with 70% reporting complete healing at 6 months. The Silicea group exhibited gradual healing, with 60% achieving symptom relief and a notable reduction in recurrence rates. No severe adverse effects were reported. The efficacy was significantly higher in the Hepar Sulph. group, particularly in reducing inflammation and promoting tissue repair. Conclusion:

Hepar Sulph. and Silicea both demonstrate therapeutic potential in the management of fistula in ano, with Hepar Sulph. proving more effective in symptom management and healing. These findings suggest that homeopathic remedies could serve as viable adjuncts or alternatives to traditional treatments. Further large-scale randomized controlled trials are recommended to validate these findings and optimize treatment protocols.

Index Terms- Fistula in Ano, Hepar Sulph., Silicea, Homeopathy, Non-surgical Treatment, Healing, Inflammation.

I. INTRODUCTION

Fistula in ano is a common yet challenging anorectal condition characterized by an abnormal connection between the anal canal and the perianal skin. It is typically the result of an untreated anal abscess or chronic inflammation, which leads to recurrent discharge, pain, and potential complications such as infection or abscess formation. The condition significantly affects the quality of life, causing physical discomfort and emotional distress for those affected. The conventional treatment for fistula in ano involves surgical intervention, such as fistulotomy or

seton placement, which, while effective, carry risks of recurrence, incontinence, and prolonged recovery times. Due to these challenges, many patients seek alternative or complementary therapies that are less invasive, such as homeopathy. Among the various homeopathic remedies, *Hepar Sulph.* and *Silicea* have garnered attention for their reported ability to support wound healing, reduce inflammation, and address chronic infections, making them potential candidates for managing fistula in ano.

Hepar Sulph. (Calcium Sulphide) is a homeopathic remedy known for its action in treating abscesses, infections, and suppurations. It is particularly useful in cases where there is significant pain, swelling, and the presence of pus. *Silicea* (Silica), on the other hand, is reputed for its ability to stimulate tissue repair and assist in the drainage of pus, making it valuable in cases of chronic fistulas and abscesses. Both remedies are considered to support the body's natural healing processes and reduce the risk of infection.

Despite their widespread use in homeopathic practice, scientific evidence regarding the efficacy of *Hepar Sulph.* and *Silicea* in the management of fistula in ano is limited. This study seeks to explore the potential benefits of these remedies, examining their effects on symptom relief, healing time, and recurrence rates in patients with fistula in ano. The goal is to evaluate whether these homeopathic treatments can serve as effective non-surgical alternatives or adjuncts to conventional therapies, thus expanding treatment options for patients and improving their overall outcomes.

II. MATERIALS AND METHODS

Study Design:

This was a randomized controlled trial (RCT) conducted to evaluate the efficacy of *Hepar Sulph.* and *Silicea* in the management of fistula in ano. Patients were randomly assigned to one of two treatment groups: *Hepar Sulph.* or *Silicea*. The study aimed to assess the impact of these homeopathic remedies on symptom relief, wound healing, and recurrence of infection over a 6-month period. The study adhered to ethical standards, and all participants provided written informed consent prior to inclusion.

Patient Selection:

Sixty patients diagnosed with fistula in ano were recruited for the study. Inclusion criteria were:

- Age between 18 and 60 years.
- Clinically diagnosed fistula in ano (verified by digital rectal examination and/or imaging).
- No prior surgical treatment or recent use of antibiotics for the condition.
- No significant comorbidities such as diabetes, immunocompromised states, or other severe systemic diseases.

Exclusion criteria included:

- Pregnancy or breastfeeding.
- Active anal cancer or other rectal pathologies.
- Patients with previous adverse reactions to homeopathic remedies.

Interventions

Patients were randomly assigned to receive either *Hepar Sulph.* or *Silicea* based on individualized homeopathic prescriptions. Treatment was administered as follows:

- *Hepar Sulph.* group: Patients were given *Hepar Sulph.* in 30C potency, administered in liquid form (5 drops in 1 teaspoon of water) three times a day.
- *Silicea* group: Patients were given *Silicea* in 30C potency, administered in the same regimen as the *Hepar Sulph.* group.

The remedies were prescribed based on the principles of homeopathy, considering the patient's specific symptoms and overall constitution. Treatment continued for a period of 6 months, with follow-up visits every month.

Outcome Measures:

Primary outcomes:

1. Symptom relief: Pain, discharge, and swelling were assessed using a visual analog scale (VAS) at baseline, 3 months, and 6 months.
2. Wound healing: The healing of the fistula tract was monitored via clinical examination and, when necessary, imaging (e.g., ultrasound or MRI) at baseline and at 3 and 6 months.
3. Recurrence rate: The recurrence of symptoms or new abscess formation was monitored over the 6-month study period.

Secondary outcomes:

1. Quality of Life (QoL): The impact of the condition on the patient's daily life was assessed using the Fistula Impact Questionnaire (FIQ) at baseline and 6 months.
2. Adverse effects: Any adverse effects or side effects from the homeopathic treatments were noted at each visit.

Data Collection:

Data were collected at baseline, 3 months, and 6 months. At each time point, patients underwent a thorough clinical assessment, including:

- Symptom severity as reported by patients.
- Physical examination of the anal region to evaluate the size and healing of the fistula.
- Imaging studies (when necessary) to monitor the progression of healing.

Statistical Analysis:

Descriptive statistics were used to summarize the demographic characteristics and baseline clinical data. Paired t-tests and Chi-square tests were used to compare changes in symptom scores, healing progress, and recurrence rates within and between groups over time. A p-value of <0.05 was considered statistically significant.

Ethical Considerations:

The study was approved by the Institutional Ethics Committee, and all participants provided informed consent. Patient confidentiality was maintained throughout the study, and they were free to withdraw from the study at any time without consequence.

III. OBSERVATION AND ANALYSIS

Demographics and Baseline Characteristics:

A total of 60 patients (30 in each group) were enrolled in the study, with ages ranging from 18 to 60 years. The demographic characteristics of both groups were comparable at baseline, with no significant differences in terms of age, gender, or disease duration. The mean age of patients was 36.5 years, and the majority of patients (60%) were male. The baseline characteristics such as the severity of symptoms (pain, discharge, and swelling) and the size of the fistula tract were similar in both groups, ensuring that the groups were comparable for statistical analysis.

Symptom Relief:

Symptom relief was the primary outcome of the study. At baseline, both groups had moderate to severe symptoms. The analysis of symptom reduction at 3 months and 6 months revealed significant improvements in both groups:

- In the *Hepar Sulph.* group, 70% of patients reported complete resolution of symptoms, including pain and discharge, by the 6-month mark. Pain scores on the VAS decreased from an average of 7.8 (baseline) to 2.3 at 6 months ($p < 0.01$).
- In the *Silicea* group, 60% of patients showed significant improvement, with pain scores reducing from an average of 7.5 (baseline) to 3.1 at 6 months ($p < 0.05$). However, symptom relief in the *Silicea* group was slightly slower compared to *Hepar Sulph.*

Both remedies were effective in reducing pain and discharge, with *Hepar Sulph.* showing faster and more complete symptom relief. The *Silicea* group experienced a gradual reduction in symptoms, which continued to improve throughout the study period.

Wound Healing:

Wound healing was assessed using clinical examination and imaging. At baseline, all patients had an open fistula tract. By the 3-month follow-up, 50% of patients in the *Hepar Sulph.* group had a closed fistula tract, compared to 30% in the *Silicea* group. By the end of the 6-month study period, 70% of the *Hepar Sulph.* group achieved complete healing of the fistula tract, while 60% of the *Silicea* group showed significant healing, but the fistula tract remained partially open in some cases. The difference in healing rates between the two groups was statistically significant ($p < 0.05$), with *Hepar Sulph.* demonstrating a superior healing rate.

Recurrence Rate:

The recurrence rate of fistula-related symptoms was also monitored. In the *Hepar Sulph.* group, only 10% of patients experienced a recurrence of symptoms within 6 months, which was mostly mild and could be managed with continued homeopathic treatment. In

contrast, the *Silicea* group had a higher recurrence rate of 20%, although the severity of recurrences was less than that observed in untreated patients.

Quality of Life (QoL) Improvement:
Both groups experienced improvements in quality of life, as measured by the Fistula Impact Questionnaire (FIQ). The *Hepar Sulph.* group showed a significant improvement in QoL scores, with a 75% increase in quality of life by the 6-month follow-up ($p < 0.01$). The *Silicea* group had a 60% improvement in QoL scores, which was still substantial but slightly lower than that of the *Hepar Sulph.* group.
Adverse Effects:
No significant adverse effects were reported in either group. A few patients in the *Hepar Sulph.* group reported mild aggravations of existing symptoms during the first two weeks of treatment, which is consistent with homeopathic aggravations. These symptoms resolved spontaneously without requiring any additional treatment. The *Silicea* group did not report any adverse reactions.

Statistical Analysis:
Data analysis revealed that both *Hepar Sulph.* and *Silicea* led to significant improvements in symptom management, healing, and quality of life compared to baseline. However, *Hepar Sulph.* showed a statistically significant advantage in terms of faster healing, greater symptom resolution, and lower recurrence rates. The differences between the two groups were analysed using paired t-tests, with a significance level of $p < 0.05$.













DISCUSSION

The present study aimed to explore the efficacy of *Hepar Sulph.* and *Silicea* in managing fistula in ano, a challenging and persistent condition. The results from this study indicate that both homeopathic remedies show promising effects, with *Hepar Sulph.* demonstrating superior outcomes in terms of symptom relief, fistula healing, and quality of life improvement when compared to *Silicea*.

Symptom Relief:

Both homeopathic remedies led to significant improvements in pain and discharge, which are among the most distressing symptoms for patients with fistula in ano. The reduction in pain scores observed in this study aligns with previous research that highlights the potential of homeopathic remedies in alleviating symptoms of chronic conditions. *Hepar Sulph.*, in particular, provided faster and more substantial pain relief, with 70% of patients achieving complete resolution of symptoms by 6 months. In contrast, the *Silicea* group demonstrated a gradual improvement, with 60% achieving relief at the 6-month mark. This suggests that *Hepar Sulph.* may act more rapidly, likely due to its specific action on the immune response and tissue repair mechanisms.

Fistula Healing:

Fistula healing is a critical outcome in the management of anal fistulas. The current study showed a significant difference in healing rates between the two groups, with *Hepar Sulph.* achieving a higher healing rate of 70% compared to 60% for *Silicea*. These results suggest that *Hepar Sulph.* may have a stronger effect on tissue regeneration and closure of the fistula tract. This finding is consistent with other studies that have indicated the effectiveness of *Hepar Sulph.* in promoting wound healing and resolving chronic infections, which is crucial for patients with anal fistulas.

Recurrence and Long-term Effectiveness:

The recurrence rate in the *Hepar Sulph.* group was lower (10%) compared to the *Silicea* group (20%), indicating that *Hepar Sulph.* may offer more sustained symptom resolution. This is a particularly important outcome, as recurrence of fistula-related symptoms often leads to repeated interventions, prolonging the patient's suffering and impacting their quality of life.

Quality of Life Improvement:

Both groups reported significant improvements in quality of life, but the *Hepar Sulph.* group demonstrated a more pronounced improvement. This is supported by the significant reduction in pain, fewer recurrences, and more complete fistula healing, all of which contribute to better overall well-being. It is noteworthy that homeopathy, as a holistic system of treatment, appears to address the multifaceted nature of fistula in ano, not only focusing on physical symptoms but also improving the psychological and emotional state of patients.

Adverse Effects:

In terms of safety, both remedies were well-tolerated, with minimal adverse effects reported. This is consistent with the generally safe profile of homeopathic treatments, which are well-suited for long-term management of chronic conditions like fistula in ano. The mild aggravations observed in the *Hepar Sulph.* group during the initial weeks are consistent with homeopathic principles, where initial exacerbations are considered a sign of therapeutic action.

CONCLUSION

This study highlights the therapeutic potential of *Hepar Sulph.* and *Silicea* in the management of fistula in ano, with *Hepar Sulph.* proving to be more effective in terms of faster symptom relief, superior healing rates, and better long-term outcomes. Both remedies showed significant improvements in pain, discharge, and quality of life, and were well-tolerated by the patients. These findings suggest that homeopathy could be a viable alternative or adjunct to conventional

treatments for fistula in ano, offering a safe and effective treatment option, particularly for those seeking a holistic approach. Further research with larger sample sizes and longer follow-up periods is needed to confirm these findings and explore the mechanisms underlying the effects of these homeopathic remedies in fistula management. In addition, randomized controlled trials comparing these treatments to conventional surgical interventions could provide valuable insights into the relative efficacy and safety of homeopathic remedies in this context.

REFERENCE

[1] Hahnemann, S. (1842). *Organon of Medicine*. 6th edition. Translated by R. E. Dudgeon. New Delhi: B. Jain Publishers.

[2] Vithoulkas, G. (2001). *The Science of Homeopathy*. New York: Thomas Nelson Inc.

[3] Henderson, A. J., & Smith, C. D. (2019). "Homeopathic treatments for fistula in ano: A comprehensive review". *Journal of Alternative Medicine*, 24(2), 145-153.

[4] Patel, S., & Thomas, T. (2017). "The role of *Hepar Sulph.* in the treatment of anal fistulas". *Homeopathy Journal*, 106(4), 215-220.

[5] Kumar, V., & Mehta, S. (2018). "A randomized controlled trial on the effect of homeopathic remedies in the management of fistula in ano". *Indian Journal of Homeopathic Research*, 22(3), 193-201.

[6] Sharma, R., & Sharma, A. (2016). "Silicea as a therapeutic remedy in chronic abscess and fistula formation". *Complementary Medicine Journal*, 12(2), 85-91.

[7] Gupta, P., & Mehta, P. (2020). "An evidence-based approach to homeopathy in the treatment of perianal fistulas". *Asian Journal of Homeopathic Studies*, 7(1), 33-42.

[8] Singh, D., & Kaur, M. (2015). "A systematic review on the use of *Silicea* in treating fistula and abscesses". *Journal of Complementary Therapies in Medicine*, 23(1), 48-56.

[9] Petersen, M. T. (2014). "The effect of homeopathic treatment on fistula in ano: A clinical trial". *Journal of Homeopathic and Integrative Medicine*, 5(1), 48-53.

[10] McCabe, L., & Kumar, A. (2013). "Homeopathic management of chronic fistula: A case series". *Alternative and Complementary Therapies*, 19(3), 148-152.